We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Novartis AG on Thursday said the U.S. Food and Drug Administration granted breakthrough-therapy designation to ligelizumab for the treatment of the skin disease chronic spontaneous urticaria in patients who have an inadequate response to H1-antihistamine treatment.
The Swiss drug maker said there are currently limited approved therapies for patients with chronic spontaneous urticaria, also known as chronic idiopathic urticaria, an unpredictable and severe skin disease that affects 0.5% to 1% of the global population at any time.
The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.
Novartis said it expects to file for U.S. approval of ligelizumab in chronic spontaneous urticaria in 2022.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 14, 2021 06:52 ET (11:52 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
